
Bshra A Alsfouk Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi ArabiaCorrespondence: Bshra A Alsfouk, Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia, Tel +966118239318, Email baalsfouk@pnu.edu.saAbstract: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction in which serotonergic signaling contributes to symptom generation and modulation. Selective serotonin reuptake inhibitors (SSRIs) have been proposed as gut-brain neuromodulators because they act on both central and peripheral serotonin pathways. Physiological studies suggest that SSRIs enhance gastric and small bowel transit, although their effects on visceral sensitivity and abdominal pain remain inconsistent. Recent meta-analysis indicates that SSRIs may provide a modest benefit for abdominal pain; however, the certainty of the evidence is low, and no significant improvement has been demonstrated for global IBS symptoms. Findings across randomized controlled trials (RCTs) and meta-analyses remain inconsistent, reflecting substantial heterogeneity in study design, patient populations, and outcome measures. The potential role of SSRIs may differ according to the IBS subtype. By accelerating gastrointestinal transit, SSRIs may be more suitable for constipation-predominant IBS, whereas tricyclic antidepressants (TCAs), which slow transit, may be preferable for diarrhea-predominant IBS. However, evidence supporting subtype-specific efficacy remains limited. Further well-designed RCTs evaluating treatment effects according to IBS phenotype are therefore needed. Current guidelines generally recommend TCAs, which have stronger evidence for efficacy, as first-line neuromodulators and SSRIs as alternative options. In clinical practice, treatment selection should extend beyond efficacy alone and consider bowel habit subtype, predominant symptoms, psychological comorbidities, adverse-effect vulnerability, patient preferences, and the likelihood of treatment acceptance, adherence, and persistence. SSRIs are well tolerated medications and may be particularly useful in selected patients, including those with IBS-constipation or coexisting anxiety, within a personalized, phenotype-informed treatment approach. Prescribers should recognize that patients may face several barriers to accepting and adhering to neuromodulators in IBS including concerns about taking an “antidepressant” for a gastrointestinal disorder, fear of adverse effects, perceived stigma, and misunderstanding of the gut–brain mechanism. Therefore, clinician-patient education and ongoing adherence monitoring are essential.Keywords: antidepressants, functional gastrointestinal disorders, gut-brain neuromodulators, IBS, irritable bowel syndrome, selective serotonin reuptake inhibitors
Tian Wang, Jin Zhou, Yunlong Wang Department of Pain Treatment (Traditional Chinese Medicine Orthopedics), Huantai County People’s Hospital, Zibo, Shandong, 256400, People’s Republic of ChinaCorrespondence: Yunlong Wang, Department of Pain Treatment (Traditional Chinese Medicine Orthopedics), Huantai County People’s Hospital, Huantai Road 2198, Huantai County, Zibo, Shandong, 256400, People’s Republic of China, Email w18505338061@126.comBackground: Percutaneous vertebroplasty has been proposed as minimally invasive treatment to stabilize fractured vertebral body and provide faster pain relief, but its comparative benefit over conservative treatment remains debated. This review compared percutaneous vertebroplasty with non-surgical controls for pain relief and safety outcomes in osteoporotic vertebral compression fractures.Methods: This review was conducted accordance with PRISMA 2020. PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched from inception to April 2026. Pain scores were pooled as standardized mean differences (SMDs) with 95% confidence intervals (CIs), while fracture outcomes and serious adverse events were pooled as risk ratios (RRs). Random-effects models were used and heterogeneity was assessed using Cochran’s Q, I2, and tau-squared.Results: A total of 20 randomized controlled trials comprising 2238 participants were included in this review. Vertebroplasty was associated with significantly greater pain reduction than non-surgical controls at 1 week (SMD=− 1.22; 95% CI: − 1.93 to − 0.50), 1 month (SMD=− 1.17; 95% CI: − 1.77 to − 0.56), 3 months (SMD=− 0.84; 95% CI: − 1.30 to − 0.38), 6 months (SMD=− 0.86; 95% CI: − 1.26 to − 0.46), and 12 months (SMD=− 0.69; 95% CI: − 1.06 to − 0.32). 3-week pain outcome was not statistically significant (SMD = − 0.49; 95% CI: − 1.24 to 0.26). No significant difference was observed for fracture risk (RR=1.04; 95% CI: 0.81 to 1.34) or serious adverse events (RR=0.58; 95% CI: 0.33 to 1.00).Conclusion: Percutaneous vertebroplasty was associated with greater pain relief than non-surgical controls treatment at all follow-up periods except 3 weeks among patients with osteoporotic vertebral compression fractures, with the strongest apparent benefit in early post-treatment period.Keywords: fracture, meta-analysis, percutaneous vertebroplasty
Noor A Aweer,1 Mayss A Dalol,2 Rowan Mesilhy,3 Ayman Abdullah Dalol,1 Aadhila Abbas Manthiri,4 Abdulrahman F Al-Mashdali,5 Mohammed Abdulgayoom,5 Tareq Abuasab,6 Motaz Almahmood,7 Shehab F Mohamed5 1College of Medicine, QU Health, Qatar University, Doha, Qatar; 2School of Medicine, The University of Jordan, Amman, Jordan; 3Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar; 4College of Pharmacy, QU Health, Qatar University, Doha, Qatar; 5Hematology Department, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar; 6Section of Hematology, Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA; 7Department of Internal Medicine, Phoenixville Hospital–Tower Health, Phoenixville, PA, USACorrespondence: Motaz Almahmood, Department of Internal Medicine, Phoenixville Hospital–Tower Health, 140 Nutt Road, Phoenixville, PA, 19460, USA, Tel +14849279118, Email motazodat71@gmail.comPurpose: Differentiated thyroid cancer has an excellent prognosis, but the long-term leukemogenic risk of radioactive iodine (RAI) remains uncertain. This scoping review evaluated the clinical characteristics, latency, cytogenetic patterns, dose-response evidence, and risk-management implications of therapy-related myeloid neoplasms after RAI exposure.Methods: Following JBI methodology and PRISMA-ScR guidance, PubMed and Embase were searched through October 2025 for studies reporting acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after iodine-131 treatment for thyroid cancer. Case-level and cohort data on cumulative RAI exposure, latency, cytogenetics, treatment, outcomes, and comparative risk estimates were extracted.Results: Twenty-five studies were included, comprising 19 case reports or series and 6 retrospective cohorts. Among 28 detailed cases, median latency was approximately 2.9 years, cumulative RAI exposure ranged from 80 to 1730 mCi (median, 261 mCi), and AML accounted for 27 of 28 cases. Recurrent abnormalities included complex karyotypes, chromosome 5q/7 abnormalities, and PML::RARA. Comparative cohort studies generally reported higher AML/MDS risk after RAI exposure, with reported hazard ratios of 1.79 and 2.21 in two large comparative cohorts. One large cohort demonstrated a dose-response association and a significant leukemia signal from cumulative exposure of at least 3.7 GBq (approximately 100 mCi).Conclusion: RAI-associated myeloid neoplasms appear to represent an uncommon but clinically relevant treatment-safety signal. The findings support risk-aware therapeutic decision-making, attention to cumulative RAI exposure, and long-term hematologic follow-up, particularly after repeated or higher cumulative activities. Because absolute risk remains low and causal attribution is limited by the available evidence, appropriate RAI therapy should not be withheld; persistent or otherwise unexplained cytopenias after treatment should prompt timely evaluation.Keywords: radioactive iodine, therapy-related myeloid neoplasms, thyroid cancer, acute myeloid leukemia, myelodysplastic syndrome, treatment safety
Zhen Lai,1,* Weijia Gao,2,* Xujing Yao,3 Shijie Cao,4 Xinyu Xia,4 Natalie Ann Parry,2 Yan Liang21Department of Acupuncture, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, People’s Republic of China; 2Department of Acupuncture, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 3Department of Acupuncture, Jiangqiao Community Health Service Center, Jiading District, Shanghai, People’s Republic of China; 4Department of Acupuncture, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yan Liang, Department of Acupuncture, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China, Email dr.liangy@163.comBackground: Whether intensive electroacupuncture (EA) during early nicotine withdrawal improves symptom trajectories remains unclear.Objective: To compare intensive EA with low-density EA and varenicline for withdrawal symptoms and explore withdrawal-related sleep symptoms.Methods: In this single-center, three-arm, open-label randomized trial, 114 participants were allocated equally to intensive EA, low-density EA, or varenicline for 4 weeks. EA was administered daily or every other day during week 1, respectively, and three times weekly during weeks 2– 4. Outcomes were assessed at baseline, weeks 1– 4, and 1 and 3 months after treatment. The main outcome for the present analysis was the week-1 change in Minnesota Nicotine Withdrawal Scale (MNWS) total score. Withdrawal-related sleep symptoms were assessed exploratorily using a score derived from two MNWS sleep-related items. Analyses used analysis of covariance and generalized estimating equations, with exploratory analyses of time-averaged symptom burden and post-treatment changes.Results: Per-protocol analyses included 110 participants. At week 1, intensive EA was associated with lower adjusted MNWS scores than varenicline (mean difference, − 5.75; 95% CI, − 6.95 to − 4.55) and low-density EA (− 5.88; 95% CI, − 7.08 to − 4.67). Exploratory analyses suggested improvements in craving and withdrawal-related sleep symptoms. The proportions with exhaled carbon monoxide ≤ 4 ppm at 3 months after treatment were 29.7%, 18.9%, and 13.9% in the intensive EA, varenicline, and low-density EA groups, respectively (overall p=0.234).Conclusion: Intensive EA may alleviate withdrawal symptoms during early smoking cessation. Exploratory sleep findings require confirmation. The study did not establish a benefit for smoking abstinence, and longer follow-up is needed.Keywords: nicotine dependence, electroacupuncture, smoking cessation, withdrawal symptoms, sleep disturbance, randomized controlled trial